Insider Buying: GSK plc (LON:GSK) Insider Purchases £9,147.46 in Stock

GSK plc (LON:GSK) insider Elizabeth (Liz) McKee Anderson bought 446 shares of the stock in a transaction on Monday, September 23rd. The shares were bought at an average cost of GBX 2,051 ($27.46) per share, for a total transaction of £9,147.46 ($12,248.88).

GSK Stock Performance

GSK stock opened at GBX 1,522 ($20.38) on Friday. GSK plc has a fifty-two week low of GBX 1,371.40 ($18.36) and a fifty-two week high of GBX 1,823.50 ($24.42). The firm’s 50 day simple moving average is GBX 1,584.23 and its 200-day simple moving average is GBX 1,628.78. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The company has a market cap of £62.10 billion, a P/E ratio of 1,346.90, a price-to-earnings-growth ratio of 1.34 and a beta of 0.31.

GSK Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Thursday, October 10th. Shareholders of record on Thursday, August 15th will be given a dividend of GBX 15 ($0.20) per share. This represents a yield of 0.97%. The ex-dividend date is Thursday, August 15th. GSK’s payout ratio is 5,309.73%.

Analyst Ratings Changes

Several research firms have recently issued reports on GSK. Shore Capital reiterated a “buy” rating on shares of GSK in a report on Wednesday, August 28th. Berenberg Bank reiterated a “buy” rating and set a GBX 1,820 ($24.37) price target on shares of GSK in a research report on Tuesday, September 10th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Monday, July 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,850 ($24.77) target price on shares of GSK in a research note on Tuesday, September 3rd. Finally, Citigroup dropped their price target on shares of GSK from GBX 2,120 ($28.39) to GBX 1,900 ($25.44) and set a “buy” rating on the stock in a research report on Friday, July 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,842.50 ($24.67).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.